- Home
- MYGN vs UTG Comparison
MYGN vs UTG Comparison
Compare MYGN & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- UTG
- Stock Information
- Founded
- MYGN 1991
- UTG 2003
- Country
- MYGN United States
- UTG United States
- Employees
- MYGN N/A
- UTG N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- UTG Investment Managers
- Sector
- MYGN Health Care
- UTG Finance
- Exchange
- MYGN Nasdaq
- UTG Nasdaq
- Market Cap
- MYGN 2.0B
- UTG 2.8B
- IPO Year
- MYGN 1995
- UTG N/A
- Fundamental
- Price
- MYGN $13.36
- UTG $31.17
- Analyst Decision
- MYGN Hold
- UTG
- Analyst Count
- MYGN 12
- UTG 0
- Target Price
- MYGN $23.92
- UTG N/A
- AVG Volume (30 Days)
- MYGN 1.1M
- UTG 319.3K
- Earning Date
- MYGN 11-07-2024
- UTG 01-01-0001
- Dividend Yield
- MYGN N/A
- UTG 9.31%
- EPS Growth
- MYGN N/A
- UTG N/A
- EPS
- MYGN N/A
- UTG N/A
- Revenue
- MYGN $823,600,000.00
- UTG N/A
- Revenue This Year
- MYGN $13.82
- UTG N/A
- Revenue Next Year
- MYGN $4.59
- UTG N/A
- P/E Ratio
- MYGN N/A
- UTG N/A
- Revenue Growth
- MYGN 12.15
- UTG N/A
- 52 Week Low
- MYGN $12.87
- UTG $23.24
- 52 Week High
- MYGN $29.30
- UTG $29.50
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- UTG 31.24
- Support Level
- MYGN $12.87
- UTG $30.76
- Resistance Level
- MYGN $15.44
- UTG $33.25
- Average True Range (ATR)
- MYGN 0.84
- UTG 0.60
- MACD
- MYGN -0.02
- UTG -0.40
- Stochastic Oscillator
- MYGN 12.37
- UTG 9.72
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.